**1. Introduction**

Hemoglobinopathies are common genetic disorders resulting from formation of one of the abnormal globin chain of the haemoglobin molecule. Sickle cell disease was first described in early 20th century. It is an inherited haemoglobinopathy resulting from a mutation occurring in beta-globin gene, on chromosome 11. The gene is prevalent in some tribes of North Maharashtra. The main aim of the study is to determine haemoglobin patterns in cases with sickle cell hemoglobinopathies in North Maharashtra using HPLC testing system. **Material and Methods:** This is a prospective study done over a period of 6 years. 10081 patients having positive solubility test or negative solubility test but having clinical suspicion of Sickle cell hemoglobinopathies were studied in detail and all samples were subjected for HPLC testing. **Results:** Prevalence of sickle cell hemoglobinopathy in this study was 70.36%. Most common pattern of haemoglobin observed was SA (89.72%). A slight female preponderance (54%) was noted. Predominant age group was paediatric (39.96%), followed by 12-20yrs (33.97%). Oldest case for HbSS was 55yrs male. Predominant category affected was ST (82.05%). **Conclusion:** A very high prevalence of Sickle cell hemoglobinopathy was noted in this study. This is because the study was done in areas where Pawara and Bhill community resides who have a high frequency of HbS gene. Solubility test was found to be cost effective and easy screening test (Sensitivity being 70.36%). HPLC found to be Rapid and accurate test for diagnosis of hemoglobinopathy and had helped in diagnosis of some rare heterozygous disorders like SA-HBQ India, SA-Hereditary persistence of foetal haemoglobin, HBD-SA. This is one of the largest and first of its kind prospective study which will help in prevention and cost effective management in targeted population.
two-fold: Small vessel obstruction by sickle cells (vaso-occlusive events which can be extremely painful) and haemolytic anaemia due to the greatly reduced half-life of SS cells when compared with normal red blood cells (12 vs. 120 days). Sickle cell trait has predominantly benign clinical picture, as the cells only sickle at very low oxygen tension. Sickle cell trait provides some protection against the consequences of Plasmodium falciparum malaria.

Sickle cell disease is a chronic debilitating disease characterized by chronic haemolytic anaemia, recurrent intermittent vaso-occlusion and severe pain, progressive organ damage and early death.

Diagnosis: Hemoglobin disorders are responsible for an extremely complex series of clinical phenotypes. Sickle cell anaemia can cause chronic ill health and life threatening situations, so it is very important to have reliable detection and identification methods for haemoglobin variants and because this can lead to the prevention of more severe disorders such as sickle cell disease in infants.

Peripheral Blood Smear examination (PBS): Examination of the peripheral blood film may reveal sickle forms or an elevated reticulocyte count relative to the haemoglobin level, but these may not be present in sickle cell trait where the red cell morphology may be essentially normal.

Solubility test: It is only screening test. False positive results can be seen.

Serum electrophoresis: It is definitive test but it does not give percentage of abnormal hemoglobins

High Performance Liquid Chromatography (HPLC): HPLC is rapid and accurate tool for diagnosis of sickle cell hemoglobinopathies.

2. Materials and Methods

2.1 Study Design
It is a hospital based prospective study carried out in GMC Dhule, a tertiary care centre over a period of 6 years. Here patients come from Dhule, Nandurbar, Nashik and Jalgaon district. All these districts have high prevalence rate of sickle cell anaemia.

2.2 Aim of Study
• To determine haemoglobin patterns in cases with sickle cell hemoglobinopathies in North Maharashtra using HPLC testing system.
• To find the categories at high risk of sickle cell hemoglobinopathies in North Maharashtra so as to target this population for cost effective prevention and management of hemoglobinopathies.
• To see demographic characteristics of these patients
• To see the sensitivity and efficacy of solubility test in screening of sickle cell hemoglobinopathies.

2.3 Period of Study
Six years from Year 2008 to 2013.

Study subject: A total 10081 patients having positive solubility test or negative solubility test but having clinical suspicion of sickle cell hemoglobinopathies were included in the study. These patients included, patients coming to OPD for investigations of anaemia, IPD patient in wards, ANC patients and patients from various camps taken in primary and secondary units.

Ethical consideration: Informed consent was taken before enrolling the patients in the study.

2.4 Data Analysis
Screening tests: Solubility test was done as screening test in all cases. All patients having positive screening test or having negative screening test but having clinical suspicion of hemoglobinopathies were subjected for HPLC studies. Diagnosis of hemoglobinopathies was made based on laboratory tests and clinical findings as mentioned in literature.

2.5 Demographic Study
Age, sex and category wise distribution of patients and patterns of hemoglobin were observed.

2.6 Procedure
• 2-3ml of blood samples were collected after obtaining informed consent using Ethylene Diamine Tetra acetic acid as an anticoagulant from each patient ensuring that they were free of blood transfusion for at least one month.
• First samples were run on cell counter to note Hb% and red blood cell indices.
• Samples were tested within a week of collection and stored at 2-8°C.
• The samples were run on BIO-RAD Variant Hemoglobin Testing System which utilizes the principle of HPLC.
• An HbA,F calibrator and two levels of controls (BIO-RAD) were analyzed at the beginning of each run. The total area acceptable was between one to three million.
3. Results

From this Table 1 it is seen that prevalence of Sickle cell hemoglobinopathies is 70.36%. Sensitivity of solubility test is also 70.36%

Table 1. HPLC report

<table>
<thead>
<tr>
<th>Result</th>
<th>Normal</th>
<th>Sickle cell hemoglobinopathies</th>
<th>Other hemoglobinopathies</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>No.</td>
<td>2716</td>
<td>7093(70.36)</td>
<td>272(2.69)</td>
<td>10081</td>
</tr>
</tbody>
</table>

From this Table 1 it is seen that prevalence of Sickle cell hemoglobinopathies is 70.36%. Sensitivity of solubility test is also 70.36%

Table 2. Sex distribution of cases

<table>
<thead>
<tr>
<th>Year</th>
<th>Male</th>
<th>Female</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>2008</td>
<td>289(47%)</td>
<td>325(53%)</td>
<td>614(100%)</td>
</tr>
<tr>
<td>2009</td>
<td>612(48%)</td>
<td>662(52%)</td>
<td>1274(100%)</td>
</tr>
<tr>
<td>2010</td>
<td>524(47%)</td>
<td>595(53%)</td>
<td>1123(100%)</td>
</tr>
<tr>
<td>2011</td>
<td>522(43%)</td>
<td>693(57%)</td>
<td>1215(100%)</td>
</tr>
<tr>
<td>2012</td>
<td>856(48%)</td>
<td>928(52%)</td>
<td>1784(100%)</td>
</tr>
<tr>
<td>2013</td>
<td>433(40%)</td>
<td>650(60%)</td>
<td>1083(100%)</td>
</tr>
</tbody>
</table>

Total 3240(46%) 3853(54%) 7093(100%)

From the given Table 2 it is seen that male to female ratio is 46/54.

Table 3. Patterns of sickle cell hemoglobinopathies

<table>
<thead>
<tr>
<th>Year</th>
<th>SA</th>
<th>SS</th>
<th>SA-BTT</th>
<th>SA-HBQ-India</th>
<th>SA-HPFHB</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>2008</td>
<td>524</td>
<td>89</td>
<td>1</td>
<td>-</td>
<td>-</td>
<td>614</td>
</tr>
<tr>
<td>2009</td>
<td>1106</td>
<td>164</td>
<td>3</td>
<td>1</td>
<td>-</td>
<td>1274</td>
</tr>
<tr>
<td>2010</td>
<td>1050</td>
<td>68</td>
<td>5</td>
<td>-</td>
<td>-</td>
<td>1123</td>
</tr>
<tr>
<td>2011</td>
<td>1103</td>
<td>105</td>
<td>5</td>
<td>1</td>
<td>1</td>
<td>1215</td>
</tr>
<tr>
<td>2012</td>
<td>1649</td>
<td>110</td>
<td>22</td>
<td>1</td>
<td>2</td>
<td>1784</td>
</tr>
<tr>
<td>2013</td>
<td>932</td>
<td>131</td>
<td>20</td>
<td>-</td>
<td>-</td>
<td>1083</td>
</tr>
</tbody>
</table>

Total 6364(89.72%) 667(9.40%) 56(0.78%) 3(0.04%) 3(0.04) 7093(100%)

SA-HPFHB- Hereditary persistence of foetal haemoglobin

Table 4. Age wise distribution of cases

<table>
<thead>
<tr>
<th>Year</th>
<th>Ped</th>
<th>12-20</th>
<th>21-30</th>
<th>31-40</th>
<th>41-50</th>
<th>&gt;50</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>2008</td>
<td>212</td>
<td>268</td>
<td>85</td>
<td>28</td>
<td>16</td>
<td>5</td>
<td>614</td>
</tr>
<tr>
<td>2009</td>
<td>458</td>
<td>470</td>
<td>232</td>
<td>59</td>
<td>42</td>
<td>13</td>
<td>1274</td>
</tr>
<tr>
<td>2010</td>
<td>438</td>
<td>415</td>
<td>180</td>
<td>45</td>
<td>33</td>
<td>12</td>
<td>1123</td>
</tr>
<tr>
<td>2011</td>
<td>502</td>
<td>402</td>
<td>198</td>
<td>60</td>
<td>39</td>
<td>14</td>
<td>1215</td>
</tr>
<tr>
<td>2012</td>
<td>655</td>
<td>548</td>
<td>433</td>
<td>66</td>
<td>62</td>
<td>20</td>
<td>1784</td>
</tr>
<tr>
<td>2013</td>
<td>570</td>
<td>307</td>
<td>147</td>
<td>30</td>
<td>22</td>
<td>7</td>
<td>1083</td>
</tr>
</tbody>
</table>

Total 2835 (39.96%) 2410(33.97%) 1275(17.97%) 288 (4.06%) 214 (3.01%) 71 (1.00%) 7093 (100%)
Table 7. Sex distribution of cases—comparison with other study

<table>
<thead>
<tr>
<th>Study</th>
<th>Male</th>
<th>Female</th>
</tr>
</thead>
<tbody>
<tr>
<td>Our study</td>
<td>45.69%</td>
<td>54.34%</td>
</tr>
<tr>
<td>Ajjack et al.17</td>
<td>48.6%</td>
<td>51.4%</td>
</tr>
</tbody>
</table>

From this Table 7 it is seen that our reports are comparable with other study.

- From the Table 8 it is seen that predominant pattern in our study was SA (89.7%). Balgir et al.16 showed SA pattern in 75.9% cases. Sickle cell homozygous patients showed HBS values more than 70% along with raised HBF levels. Our findings are comparable with study by Kar et al.18.
- HPLC has helped in identification of compound heterozygous disorders like SA-BTT, SA-HBQ India, SA- Hereditary persistence of foetal Hb, HBD-SA. These were diagnosed based on quantification of levels of HBE, HBS and HBA.

When compared with other study our study shows predominant category affected was ST category. It is established that sickle cell gene harbour amongst different caste groups but very high prevalence amongst SC, ST and OBC category19,20. The castes residing here like Bhil, Pawara, Konkana etc come under ST Category which carries high prevalence of sickle cell hemoglobinopathies.
- It is also observed that solubility has a sensitivity of 70.36%. It is a good screening test as it is cost effective and easy test and can rule out sickle cell hemoglobinopathy in clinically nonsuspicious cases. This will avoid burden on HPLC testing as it is a costly test.

5. Conclusion

- Prevalence of sickle cell hemoglobinopathy in this study was 70.36%.
- Our study showed a slight female preponderance (54%) over male (46%).
• Predominant sickle cell hemoglobinopathy in our study was sickle cell trait (89.72%).
• The most common age group was paediatric (0-12yrs) i.e., 39.96%, followed by 12-20 yrs (33.97%) and least common was age more than 50 yrs (1%).
• Sickle cell Hemoglobinopathy was most prevalent in ST category (82.05%) as Pawara and Bhill community in this region belongs to this category.
• We encountered some rare compound heterozygous conditions like SA-HBQ India, SA-Hereditary persistence of foetal haemoglobin, HBD-SA.
• HPLC provides rapid and accurate tool for diagnosis of hemoglobinopathies as identification of abnormal hemoglobin based on electrophoretic mobility is only presumptive and have to be confirmed by another technique applying different principle.
• To the best of our knowledge, it is one of the largest and the first of its kind study reported from North Maharashtra.
• This study helps us to focus on communities and categories having high prevalence of sickle cell gene, so it may help us in prevention by screening programme, genetic counselling and public education as well as cost effective management of patients.

6. Acknowledgement

Great regard to Staff-Sickle Cell Project, Shri Bhausaheb Hire Government Medical college, Dhule. Mr. Sunil Pawar-Technician and Mr. Laxman Salunkhe-Technician of sickle cell project.

7. Competing Interests

None declared.

8. References